| Date | Title | Description |
| 26.03.2026 | Keymed Biosciences Announces 2025 Annual Results and Business Updates | BEIJING, March 26, 2026 /PRNewswire/ -- Keymed Biosciences (HKEX: 02162) announced its 2025 annual results. The year marked the company's 10th anniversary and a pivotal year in its transition from R&D to commercialization.
Revenue Leaps... |
| 05.03.2026 | Prolium Bioscience Raises $50M in Series A Funding | Prolium Bioscience, a NYC-based clinical stage biotechnology company, raised $50M in Series A funding.
The round was led by RTW Investments (RTW).
The company intends to use the funds to expand operations and its R&D efforts.
Led by CEO... |
| 09.10.2025 | China’s InnoCare Tumbles After Licensing Three Novel Drugs to US Peer Zenas | (Yicai) Oct. 9 -- InnoCare Pharma’s share price skidded after the Beijing-based company licensed three innovative drugs to US firm Zenas BioPharma in a deal worth more than USD2 billion.
InnoCare [SHA: 688428] closed 6.3 percent lower at CN... |
| 14.05.2025 | China's InnoCare Turns First Profit in First Quarter | (Yicai) May 14 -- InnoCare Pharma posted a profit in the first quarter of this year for the first time, mainly thanks to a surge in sales of the Chinese firm's core leukemia drug.
Net profit was CNY18 million (USD2.5 million) in the three m... |
| 21.01.2025 | InnoCare, Keymed sell ex-China rights for bispecific to RTW-built biotech in $520M deal | Chinese biotechs InnoCare Pharma and KeyMed Biosciences have sold the international rights to a clinical-stage bispecific antibody to a new company created by RTW Investments for $17.5 million in near-term cash.
The CD20xCD3 antibody, known... |
| 14.07.2023 | InnoCare and ArriVent Announce Clinical Development Collaboration | Companies will collaborate on investigating a novel SHP2 inhibitor in combination with furmonertinib, a highly brain-penetrant, broadly active mutation-selective EGFR inhibitor, in patients with advanced non-small cell lung cancer
/EIN News... |
| 23.03.2022 | InnoCare Releases 2021 Annual Results and Business Highlights | BEIJING, March 23, 2022 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced 2021 annual results as of 31 December 2021.
Dr. Jasmine Cui, Co-founder, ... |
| 14.03.2022 | InnoCare Announces Acceptance of Supplemental New Drug Application for Orelabrutinib in Relapsed or Refractory Waldenström's Macroglobulinemia in China | BEIJING, March 14, 2022 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company, announced today that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) accepted a su... |
| 02.03.2022 | InnoCare Announces Approval of Phase II Clinical Trial Using Orelabrutinib for the Treatment of NMOSD in China | BEIJING, March 2, 2022 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company, announced today the Investigational New Drug (IND) approval of its Bruton's tyrosine kinase (BTK) inhibitor orelabrutinib by China Na... |
| 22.02.2022 | InnoCare Announces Dosing of First Patient in Phase II Clinical Trial Using Orelabrutinib for the Treatment of ITP | BEIJING, Feb. 22, 2022 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company, announced today that the first patient has been dosed in Phase II clinical trial of its Bruton's tyrosine kinase (BTK) inhibitor orel... |
| 18.01.2022 | InnoCare and Keymed Jointly Announce Dosing of First Patient in Clinical Trial of CD20xCD3 Bispecific Antibody CM355 | BEIJING, Jan. 18, 2022 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969) and Keymed Biosciences (HKEX: 02162) jointly announced today that the first patient in China has been dosed in clinical trial of CM355, a CD20xCD3 bispecific antibody deve... |
| 07.01.2022 | InnoCare to Attend Upcoming Investor Conferences to Share Latest Company Development | BEIJING, Jan. 7, 2022 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969), a leading biotech company, announced today that the company executives will attend the upcoming investor conferences organized by Morgan Stanley and UBS to share company's... |
| 14.12.2021 | Orelabrutinib Data Presented at the 63rd Annual Meeting of ASH | BEIJING, Dec. 14, 2021 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969), a leading biotech company, announced today that leading PIs presented latest data of BTK inhibitor orelabrutinib at the 63rd American Society of Hematology (ASH) Annual M... |
| 03.12.2021 | InnoCare Announces Inclusion of Orelabrutinib in China National Reimbursement Drug List | BEIJING, Dec. 3, 2021 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969), a commercial-stage biotech company, announced today that its BTK inhibitor orelabrutinib has been included in the updated National Reimbursement Drug List (NRDL) by the Ch... |
| 15.11.2021 | InnoCare Announces the Clearance of Clinical Trial of Novel SHP2 Allosteric Inhibitor ICP-189 by U.S. FDA | BEIJING, Nov. 15, 2021 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969), a commercial-stage biotech company, announced today the Investigational New Drug (IND) clearance of its SHP2 (Src Homology 2 domain containing protein tyrosine phosphatas... |
| 12.11.2021 | InnoCare to Attend Upcoming Investor Conferences to Share Latest Company Development | BEIJING, Nov. 12, 2021 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969), a leading biotech company, announced today that the company executives will attend the upcoming investor conferences organized by Goldman Sachs and Morgan Stanley to shar... |
| 09.11.2021 | InnoCare to Present Orelabrutinib Data at the Upcoming 63rd Annual Meeting of ASH | BEIJING, Nov. 9, 2021 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969), a leading biotech company, announced today that the company will present latest data of its BTK inhibitor orelabrutinib at the 63rd American Society of Hematology (ASH) An... |
| 19.10.2021 | InnoCare Announces Approval of Clinical Trial of Novel SHP2 Allosteric Inhibitor ICP-189 in China | BEIJING, Oct. 19, 2021 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969) announced today that the Company has received Investigational New Drug (IND) approval from the NMPA for its SHP2 (Src Homology 2 domain containing protein tyrosine phospha... |
| 31.08.2021 | InnoCare Announces Clearance by U.S. FDA of Clinical Trial of pan-TRK Inhibitor ICP-723 | BEIJING, Aug. 31, 2021 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969), a commercial-stage biopharmaceutical company, announced today the Investigational New Drug (IND) clearance of its second-generation pan-TRK inhibitor ICP-723 by the US Fo... |
| 29.08.2021 | InnoCare Releases 2021 Half Year Results and Business Highlights | BEIJING, Aug. 29, 2021 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced 2021 half year results which ended on June 30, 2021.
Dr. Jasmine Cui, Co-f... |
| 16.08.2021 | InnoCare Announces First Subject Dosed in Clinical Trial of ICP-332 | BEIJING, Aug. 16, 2021 /PRNewswire/ -- InnoCare (HKEX: 09969), a leading biopharmaceutical company focusing on drug innovation for cancer and autoimmune diseases, announced today the first subject dosed in clinical trial of novel TYK2 (Tyro... |
| 11.08.2021 | InnoCare Announces Approval of Phase II Clinical Trial Using Orelabrutinib for the Treatment of ITP in China | BEIJING, Aug. 11, 2021 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company, announced today the Investigational New Drug (IND) approval of its Bruton's tyrosine kinase (BTK) inhibitor orelabrutinib by China Na... |
| 28.06.2021 | InnoCare Announces Breakthrough Therapy Designation of Orelabrutinib by US FDA for Treatment of R/R MCL | BEIJING, June 28, 2021 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to its Bruton's t... |
| 25.06.2021 | InnoCare Announces Approval of Initiation of Phase 1 Clinical Trial of RTK Inhibitor ICP-033 in China | BEIJING, June 25, 2021 /PRNewswire/ -- InnoCare (HKEX: 09969), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, announced today that China's National Medical Products Administration (NMPA) has approved the ini... |
| 18.06.2021 | InnoCare Presents Latest Clinical Data of Orelabrutinib at the16th International Conference on Malignant Lymphoma | BEIJING, June 18, 2021 /PRNewswire/ -- InnoCare (HKEX: 09969), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, announced today the company presented the latest clinical data of the Bruton's tyrosine kinase (B... |
| 17.06.2021 | InnoCare Announces Orphan Drug Designation of Gunagrabtinib by US FDA for Treatment of Cholangiocarcinoma | BEIJING, June 17, 2021 /PRNewswire/ -- InnoCare (HKEX: 09969), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, announced today that the US Food and Drug Administration (FDA) has granted Orphan Drug Designatio... |
| 28.02.2021 | InnoCare Appoints Dr. Sean Zhang as Chief Medical Officer | BEIJING--(BUSINESS WIRE)--Feb 28, 2021--
InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, announced today that the Company appointed Dr. Sean Zhang as Chief Medical Officer (CMO)... |
| 14.12.2020 | Loyal Valley Capital Achieves 11 IPOs In 2020 With Pop Mart Listing In Hong Kong | Leading designer collectibles maker Pop Mart becomes latest fast-growth Chinese company to stage IPO after backing from Shanghai-based private equity firm Loyal Valley Capital
Shanghai, 11 Dec 2020: Private equity firm Loyal Valley Capital... |
| 11.03.2020 | Is HKEX ready to return to biotech business? InnoCare tests waters with hopes to fetch $257M in IPO | The Covid-19 outbreak may have forced InnoCare Pharma to postpone investor meetings ahead of its public debut on the Hong Kong Stock Exchange, but it hasn’t stopped the biotech from carrying on with an IPO that could bring in $2... |
| 09.02.2018 | Healthcare investment firm Vivo Capital leads $55m round in Beijing Innocare | Premium
Healthcare investment firm Vivo Capital has led the $55-million funding round of Beijing Innocare, a biopharmaceutical company that develops treatment for cancer and autoimmune diseases, with CCB Capital also backing the round.
Cont... |
| - | InnoCare to Hold 2021 R&D Day on April 15, 2021 | BEIJING--(BUSINESS WIRE)--Mar 15, 2021--
InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced that the Company will hold 2021 R&D Day themed on “Science Drives In... |
| - | InnoCare to Host 2020 Full Year Earnings Call on March 29, 2021 | BEIJING--(BUSINESS WIRE)--Mar 11, 2021--
InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced that it will host a conference call to discuss the 2020 full year financ... |
